# Tesaro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tesaro

- Industry: Pharmaceuticals
- Headquarters: Waltham, US
- Website: www.tesarobio.com
- Total disclosed funding: $60M
- Latest round: Series B (Jun 6, 2011)
- Investors on record: 8

## About

Tesaro, Inc., based in the US, is an oncology-focused company dedicated to developing innovative cancer therapies, particularly PARP inhibitors that enhance treatment outcomes for cancer patients.Founded in 2010 by Mary Hedley in Waltham, US, Tesaro, Inc. specializes in oncology therapeutics. The company underwent a significant transition in March 2013 when it raised USD 91.2 mn through the sale of shares. Tesaro was acquired by GlaxoSmithKline Plc, completing a Trade Sale that raised a total of USD 5,100 mn, marking a pivotal point in its business trajectory.Tesaro, Inc. focuses on the development and commercialization of innovative oncology therapies, particularly PARP inhibitors, which are essential in treating ovarian cancer and other malignancies. These therapies inhibit the enzyme poly(ADP-ribose) polymerase, aiding in cancer cell damage and enhancing treatment efficacy. Their products primarily target healthcare providers and oncologists in North America and Europe, with distribution in hospitals, outpatient clinics, and specialized oncology centers.In 2017, Tesaro reported a revenue of USD 223.33 mn, alongside an EBITDA of USD -469.99 mn, reflecting its financial performance during that year.Tesaro is exploring opportunities for future growth by expanding its portfolio of oncology products, particularly aiming to introduce innovative treatments in the coming years. The company plans to penetrate new geographic markets, focusing on regions like Europe and Asia by 2025. The recent Trade Sale, which raised USD 5,100 mn, is expected to support these expansion initiatives alongside further research and development efforts.

## Funding rounds

- Series B, Jun 6, 2011, $40M — InterWest Partners, Kleiner Perkins, New Enterprise Associates, T Rowe Price, Pappas Capital, Deerfield Capital Management, Oracle Capital Partners, Leerink Partners
- Series A, May 26, 2010, $20M — New Enterprise Associates

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series B
- Deerfield Capital Management (https://capitalatlas.ai/funds/deerfield-capital-management) — Series B
- Oracle Capital Partners (https://capitalatlas.ai/funds/oracle-capital-partners) — Series B
- Leerink Partners — Series B